Connect
MJA
MJA

The value of participating in clinical trials: the whole is greater than the sum of its parts

John R Zalcberg and Michael Friedlander
Med J Aust 2018; 209 (10): 424-425. || doi: 10.5694/mja17.01266
Published online: 19 November 2018

Engaging clinicians in the process of trial design, and the ensuing dialogue about best practice, can improve routine care

Evidence-based medicine remains the Holy Grail for clinicians and policy makers, and is dependent on the results of large randomised phase 3 clinical trials and on meta-analyses of all related phase 3 trials of treatment in a specific patient population.1 Irrespective of whether clinical trials test a new intervention or a drug or are comparative effectiveness studies, the findings have the potential to not only affect routine clinical practice but to inform the evidence base to lay a solid foundation for optimal care in the future as well as raise new research questions. The cost of these large trials and the resources required to mount such studies are considerable, which inevitably raises questions about whether the study is essential to answer a clinical question. Indeed, it is not uncommon to be asked by grant reviewers “do we need to do these studies in Australia?”

  • John R Zalcberg1
  • Michael Friedlander2

  • 1 The Alfred Centre; Monash University, Melbourne, VIC
  • 2 Prince of Wales Hospital, Sydney, NSW

Correspondence: john.zalcberg@monash.edu

Acknowledgements: 

We thank Steve Webb (Royal Perth Hospital), Peter Downie (Monash Children’s Hospital) and Trevor Leong (Peter MacCallum Cancer Centre).

Competing interests:

John Zalcberg is Chair of the Australian Clinical Trials Alliance.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.